PMC:7076992 / 3261-3826 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T8","span":{"begin":115,"end":121},"obj":"Body_part"},{"id":"T9","span":{"begin":238,"end":252},"obj":"Body_part"},{"id":"T10","span":{"begin":471,"end":476},"obj":"Body_part"}],"attributes":[{"id":"A8","pred":"fma_id","subj":"T8","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A9","pred":"fma_id","subj":"T9","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A10","pred":"fma_id","subj":"T10","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"There are currently over 30,000 recovered COVID-19 patients, who could present a valuable resource of convalescent plasma for health care providers. China National Biotec Group Co has claimed that 10 seriously ill patients receiving this immunoglobulin therapy demonstrated improved oxygenation and reduced inflammation and viral load [7]. High-titer specific antibodies should be able to bind to SARS-CoV-2 and neutralize the viral particles, block access to uninfected cells, and activate potent effector mechanisms (e.g., complement activation and phagocytosis)."}

{"project":"LitCovid_AGAC","denotations":[{"id":"p19822s20","span":{"begin":299,"end":306},"obj":"NegReg"},{"id":"p19822s21","span":{"begin":307,"end":319},"obj":"CPA"},{"id":"p19822s23","span":{"begin":324,"end":334},"obj":"CPA"}],"text":"There are currently over 30,000 recovered COVID-19 patients, who could present a valuable resource of convalescent plasma for health care providers. China National Biotec Group Co has claimed that 10 seriously ill patients receiving this immunoglobulin therapy demonstrated improved oxygenation and reduced inflammation and viral load [7]. High-titer specific antibodies should be able to bind to SARS-CoV-2 and neutralize the viral particles, block access to uninfected cells, and activate potent effector mechanisms (e.g., complement activation and phagocytosis)."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T18","span":{"begin":42,"end":50},"obj":"Disease"},{"id":"T19","span":{"begin":307,"end":319},"obj":"Disease"},{"id":"T20","span":{"begin":397,"end":405},"obj":"Disease"}],"attributes":[{"id":"A18","pred":"mondo_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A19","pred":"mondo_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/MONDO_0021166"},{"id":"A20","pred":"mondo_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"There are currently over 30,000 recovered COVID-19 patients, who could present a valuable resource of convalescent plasma for health care providers. China National Biotec Group Co has claimed that 10 seriously ill patients receiving this immunoglobulin therapy demonstrated improved oxygenation and reduced inflammation and viral load [7]. High-titer specific antibodies should be able to bind to SARS-CoV-2 and neutralize the viral particles, block access to uninfected cells, and activate potent effector mechanisms (e.g., complement activation and phagocytosis)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T19","span":{"begin":79,"end":80},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T20","span":{"begin":115,"end":121},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T21","span":{"begin":180,"end":183},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T22","span":{"begin":471,"end":476},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T23","span":{"begin":482,"end":490},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T24","span":{"begin":536,"end":546},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"}],"text":"There are currently over 30,000 recovered COVID-19 patients, who could present a valuable resource of convalescent plasma for health care providers. China National Biotec Group Co has claimed that 10 seriously ill patients receiving this immunoglobulin therapy demonstrated improved oxygenation and reduced inflammation and viral load [7]. High-titer specific antibodies should be able to bind to SARS-CoV-2 and neutralize the viral particles, block access to uninfected cells, and activate potent effector mechanisms (e.g., complement activation and phagocytosis)."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T17","span":{"begin":177,"end":179},"obj":"Chemical"},{"id":"T18","span":{"begin":498,"end":506},"obj":"Chemical"}],"attributes":[{"id":"A17","pred":"chebi_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/CHEBI_27638"},{"id":"A18","pred":"chebi_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/CHEBI_35224"}],"text":"There are currently over 30,000 recovered COVID-19 patients, who could present a valuable resource of convalescent plasma for health care providers. China National Biotec Group Co has claimed that 10 seriously ill patients receiving this immunoglobulin therapy demonstrated improved oxygenation and reduced inflammation and viral load [7]. High-titer specific antibodies should be able to bind to SARS-CoV-2 and neutralize the viral particles, block access to uninfected cells, and activate potent effector mechanisms (e.g., complement activation and phagocytosis)."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T1","span":{"begin":307,"end":319},"obj":"http://purl.obolibrary.org/obo/GO_0006954"},{"id":"T2","span":{"begin":525,"end":546},"obj":"http://purl.obolibrary.org/obo/GO_0006956"},{"id":"T3","span":{"begin":551,"end":563},"obj":"http://purl.obolibrary.org/obo/GO_0006909"}],"text":"There are currently over 30,000 recovered COVID-19 patients, who could present a valuable resource of convalescent plasma for health care providers. China National Biotec Group Co has claimed that 10 seriously ill patients receiving this immunoglobulin therapy demonstrated improved oxygenation and reduced inflammation and viral load [7]. High-titer specific antibodies should be able to bind to SARS-CoV-2 and neutralize the viral particles, block access to uninfected cells, and activate potent effector mechanisms (e.g., complement activation and phagocytosis)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T26","span":{"begin":0,"end":148},"obj":"Sentence"},{"id":"T27","span":{"begin":149,"end":339},"obj":"Sentence"},{"id":"T28","span":{"begin":340,"end":565},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"There are currently over 30,000 recovered COVID-19 patients, who could present a valuable resource of convalescent plasma for health care providers. China National Biotec Group Co has claimed that 10 seriously ill patients receiving this immunoglobulin therapy demonstrated improved oxygenation and reduced inflammation and viral load [7]. High-titer specific antibodies should be able to bind to SARS-CoV-2 and neutralize the viral particles, block access to uninfected cells, and activate potent effector mechanisms (e.g., complement activation and phagocytosis)."}

{"project":"LitCovid-PubTator","denotations":[{"id":"81","span":{"begin":51,"end":59},"obj":"Species"},{"id":"82","span":{"begin":214,"end":222},"obj":"Species"},{"id":"83","span":{"begin":397,"end":407},"obj":"Species"},{"id":"84","span":{"begin":42,"end":50},"obj":"Disease"},{"id":"85","span":{"begin":307,"end":319},"obj":"Disease"}],"attributes":[{"id":"A81","pred":"tao:has_database_id","subj":"81","obj":"Tax:9606"},{"id":"A82","pred":"tao:has_database_id","subj":"82","obj":"Tax:9606"},{"id":"A83","pred":"tao:has_database_id","subj":"83","obj":"Tax:2697049"},{"id":"A84","pred":"tao:has_database_id","subj":"84","obj":"MESH:C000657245"},{"id":"A85","pred":"tao:has_database_id","subj":"85","obj":"MESH:D007249"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"There are currently over 30,000 recovered COVID-19 patients, who could present a valuable resource of convalescent plasma for health care providers. China National Biotec Group Co has claimed that 10 seriously ill patients receiving this immunoglobulin therapy demonstrated improved oxygenation and reduced inflammation and viral load [7]. High-titer specific antibodies should be able to bind to SARS-CoV-2 and neutralize the viral particles, block access to uninfected cells, and activate potent effector mechanisms (e.g., complement activation and phagocytosis)."}